THE BASIC PRINCIPLES OF PANOBINOSTAT

Notwithstanding many setbacks, a number of MDM2 inhibitors have now progressed into late-phase clinical advancement. New tactics have also been developed to improve the efficacy of MDM2 inhibitors and to mitigate their on-goal toxicity. With this overview, we summarize the development and troubles in the event of a MDM2 targeted therapy.BACKGROUNDD